155 related articles for article (PubMed ID: 6191561)
21. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
Woodcock TM; Schneider RJ; Young CW
Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893
[TBL] [Abstract][Full Text] [Related]
22. Acute ventricular fibrillation and death during infusion of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA).
Von Hoff DD; Elson D; Polk G; Coltman C
Cancer Treat Rep; 1980; 64(2-3):356-8. PubMed ID: 6931630
[No Abstract] [Full Text] [Related]
23. A phase II evaluation of m-AMSA, 4'-(9-acridinylamino) methanesulfon-m-anisidide, in patients with breast cancer.
Currie VE; Howard J; Wittes R
Cancer Clin Trials; 1981; 4(3):249-51. PubMed ID: 6895189
[TBL] [Abstract][Full Text] [Related]
24. Prediction of complete remission in patients with refractory acute leukemia treated with AMSA.
Estey EH; Keating MJ; Smith TL; McCredie KB; Legha SS; Walters RS; Bodey GP; Freireich EJ
J Clin Oncol; 1984 Feb; 2(2):102-6. PubMed ID: 6583328
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults.
Legha SS; Keating MJ; McCredie KB; Bodey GP; Freireich EJ
Blood; 1982 Aug; 60(2):484-90. PubMed ID: 6953987
[TBL] [Abstract][Full Text] [Related]
26. Phase II evaluation of m-AMSA (4'-(9-acridinylamino)-methanesulfon-m-anisidide) in patients with adenocarcinoma of the pancreas.
Sternberg CN; Magill GB; Sordillo PP; Cheng E; Currie VE
Am J Clin Oncol; 1983 Aug; 6(4):459-62. PubMed ID: 6688151
[TBL] [Abstract][Full Text] [Related]
27. Intrathecally administered m-AMSA in the rhesus monkey.
Gormley P; Riccardi R; O'Neill D; Poplack D
Cancer Drug Deliv; 1984; 1(2):101-7. PubMed ID: 6549572
[TBL] [Abstract][Full Text] [Related]
28. [Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
Horikoshi N; Ogawa M; Inagaki J; Ezaki K; Inoue K; Okabe K; Nagata T; Aiba K; Domyo M
Gan To Kagaku Ryoho; 1982 Feb; 9(2):244-9. PubMed ID: 6897858
[TBL] [Abstract][Full Text] [Related]
29. [Combination of AMSA-high dose cytosine arabinoside in acute leukemia].
Zittoun R; Rio B; Marie JP; Blanc CM
Presse Med; 1985 Jun; 14(26):1417-20. PubMed ID: 3161047
[TBL] [Abstract][Full Text] [Related]
30. Amsacrine alone or in combination with 5-azacytidine and etoposide in refractory or relapsed acute non lymphoblastic leukemia (ANLL).
Carella AM; Santini G; Martinengo M; Nati S; Giordano D; Congiu A; Cerri R; Damasio E; Risso M; Rossi E
Haematologica; 1985; 70(1):39-43. PubMed ID: 2408974
[No Abstract] [Full Text] [Related]
31. Amsacrine (m-AMSA): a new antineoplastic agent. Pharmacology, clinical activity and toxicity.
Hornedo J; Van Echo DA
Pharmacotherapy; 1985; 5(2):78-90. PubMed ID: 2582401
[TBL] [Abstract][Full Text] [Related]
32. Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphoma.
Willemze R; Peters WG; van Hennik MB; Fibbe WE; Kootte AM; van Berkel M; Lie R; Rodenburg CJ; Veltkamp JJ
Scand J Haematol; 1985 Jan; 34(1):83-7. PubMed ID: 3855571
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.
Tschopp L; von Fliedner VE; Sauter C; Maurice P; Gratwohl A; Fopp M; Cavalli F
J Clin Oncol; 1986 Mar; 4(3):318-24. PubMed ID: 3456425
[TBL] [Abstract][Full Text] [Related]
34. Five-day 4'-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia.
Freund M; Giller S; Hinrichs F; Baars A; Meran J; Körfer A; Link H; Poliwoda H
J Cancer Res Clin Oncol; 1991; 117(5):489-92. PubMed ID: 1890142
[TBL] [Abstract][Full Text] [Related]
35. [Case of refractory acute myeloblastic leukemia who achieved complete remission by a new anti-leukemic agent, 4'-(9-acridinylamino) methanesulfon-m-anisidide (AMSA)].
Nagura E; Kawashima K; Suzuki H; Ohno R; Yamada K; Yokomaku S; Ogawa M
Rinsho Ketsueki; 1983 May; 24(5):632-8. PubMed ID: 6577212
[No Abstract] [Full Text] [Related]
36. Phase II clinical evaluation of intravenous 4'-(9-acridinylamino)methanesulfon-m-anisidide in colorectal cancer.
Valdivieso M; Stroehlein JR; Bedikian AY; Karlin DA; Legha SS; Bennetts RW; Bodey GP
Am J Clin Oncol; 1983 Feb; 6(1):39-44. PubMed ID: 6687657
[TBL] [Abstract][Full Text] [Related]
37. Phase II. Trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in the treatment of advanced non-Hodgkin's lymphoma.
Warrell RP; Straus DJ; Young CW
Cancer Treat Rep; 1980; 64(10-11):1157-8. PubMed ID: 6893952
[TBL] [Abstract][Full Text] [Related]
38. Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study.
Steuber CP; Holbrook T; Camitta B; Land VJ; Sexauer C; Krischer J
Invest New Drugs; 1991 May; 9(2):181-4. PubMed ID: 1714886
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer.
Legha SS; Blumenschein GR; Buzdar AU; Hortobagyi GN; Bodey GP
Cancer Treat Rep; 1979; 63(11-12):1961-4. PubMed ID: 526929
[TBL] [Abstract][Full Text] [Related]
40. Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) in patients with gastric adenocarcinoma.
Sordillo PP; Magill GB; Gralla RJ; Kelsen DP
Am J Clin Oncol; 1982 Jun; 5(3):273-5. PubMed ID: 6896259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]